Acorda Therapeutics, Inc. operates as a biopharmaceutical enterprise focused on researching, developing, and bringing to market medical treatments for neurological conditions, predominantly in the United States. The company offers Ampyra (dalfampridine), an oral medication aimed at enhancing walking capabilities in adult patients experiencing multiple sclerosis. Furthermore, it sells Inbrija, an inhaled formulation of levodopa, which is prescribed for the temporary management of "OFF" episodes in individuals with Parkinson's disease who are already on a carbidopa/levodopa regimen. Ampyra is also distributed internationally as Fampyra across markets in Europe, Asia, and the Americas. Acorda also holds a partnership and licensing arrangement with Biogen Inc. regarding the development and commercialization of Ampyra. Established in 1995, the company's main office is situated in Pearl River, New York. A notable recent event is the filing of a voluntary petition for reorganization under Chapter 11 by Acorda Therapeutics, Inc. and its associated entities on April 1, 2024, in the U.S. Bankruptcy Court for the Southern District of New York.
